The European HBV Registry: A joint initiative of TherVacB and DZIF (HBV Registry)

Study identification

• EU PAS number:
  EUPAS42767
• Study ID:
  49036
• Official title and acronym:
  The European HBV Registry: A joint initiative of TherVacB and DZIF (HBV Registry)
• DARWIN EU® study:
  No
• Study countries:
  Germany

  Italy

  Spain

  United Kingdom
• Study description:
  In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and co-infections. ; The partners will build up a European-wide registry to be able to stratify patients for upcoming clinical trials. Extensive analyses of virus and host-specific parameters are to be carried out from these patients. ; The knowledge gained thereby should contribute to a better understanding of the HBV control and enable patient stratification with regard to immunomodulatory therapies. ; Furthermore, hepatitis B patients are to be identified who are willing to participate in future studies to investigate immunotherapies to cure HBV infections (e.g. therapeutic vaccines).
• Study status:
  Ongoing

Research institutions and networks

Institutions

Hannover Medical School (MHH)

UKE Hamburg, Germany, TUM-MRI Munich, Germany, UK Leipzig Leipzig, Germany, FCRB Barcelona, Spain, AOP Parma, Italy, RFH London, UK, BLT London, UK

Networks

TherVacB, DZIF

Study timelines

Date when funding contract was signed

Actual: 01/01/2020

Study start date

Actual: 06/05/2021

Date of final study report

Planned: 31/12/2026

Sources of funding

EU institutional research programme

Other

More details on funding

BMBF, Horizon 2020

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable